CONMED's Q3 Net Income Plunges 94% Despite Sales Growth

TL;DR

**CONMED's Q3 earnings are a disaster, showing sales growth but a massive profit collapse; steer clear until they fix their cost structure.**

AI Summary

CONMED Corp reported a significant decline in net income for the three and nine months ended September 30, 2025, despite an increase in net sales. For the three months, net income plummeted to $2.859 million from $48.984 million in the prior year, a decrease of 94.2%. Diluted EPS also fell sharply to $0.09 from $1.57. Net sales, however, increased by 6.7% to $337.926 million from $316.701 million. This disparity is largely due to a substantial rise in cost of sales, which increased by 24.8% to $171.807 million, and a 40.7% surge in selling and administrative expenses to $140.339 million. For the nine months, net income decreased by 69.3% to $30.316 million from $98.668 million, while net sales grew by 4.2% to $1.001 billion. The company's balance sheet shows an increase in total assets to $2.322 billion from $2.306 billion at December 31, 2024, driven by higher cash and cash equivalents of $38.929 million and increased inventories of $364.355 million. Long-term debt decreased to $853.007 million from $905.066 million, indicating some debt reduction efforts.

Why It Matters

This filing reveals a concerning trend for CONMED investors: significant top-line growth is not translating to the bottom line. The dramatic increase in cost of sales and selling and administrative expenses suggests potential operational inefficiencies or aggressive spending that is eroding profitability. This could impact investor confidence, potentially leading to a stock price decline as the market re-evaluates the company's earnings power. For employees, this could signal pressure on margins and potentially future cost-cutting measures. Customers might see price adjustments if the company attempts to recover increased costs. In a competitive medical technology market, CONMED's inability to convert sales into profit could make it vulnerable to more efficient rivals.

Risk Assessment

Risk Level: high — The risk level is high due to the severe decline in net income for both the three-month period (down 94.2% to $2.859 million) and the nine-month period (down 69.3% to $30.316 million), despite an increase in net sales. This indicates significant margin compression, with cost of sales rising 24.8% and selling and administrative expenses increasing 40.7% for the quarter, severely impacting profitability.

Analyst Insight

Investors should exercise extreme caution and consider reducing exposure to CNMD. The significant decline in net income, driven by rising costs, suggests fundamental operational challenges. Await further clarity from management on how they plan to address these escalating expenses and restore profitability before considering any new investment.

Financial Highlights

debt To Equity

1.30

revenue

$337.9M

operating Margin

3.5%

total Assets

$2.322B

total Debt

$853.753M

net Income

$2.86M

eps

$0.09

gross Margin

49.2%

cash Position

$38.9M

revenue Growth

+6.7%

Revenue Breakdown

Key Numbers

• $337.9M — Net Sales (Q3 2025) (Increased by 6.7% from $316.7M in Q3 2024)
• $2.86M — Net Income (Q3 2025) (Decreased by 94.2% from $48.98M in Q3 2024)
• $0.09 — Diluted EPS (Q3 2025) (Fell from $1.57 in Q3 2024)
• $171.8M — Cost of Sales (Q3 2025) (Increased by 24.8% from $137.7M in Q3 2024)
• $140.3M — Selling & Admin Expense (Q3 2025) (Increased by 40.7% from $99.7M in Q3 2024)
• $1.001B — Net Sales (YTD Sept 2025) (Increased by 4.2% from $961.07M in YTD Sept 2024)
• $30.3M — Net Income (YTD Sept 2025) (Decreased by 69.3% from $98.67M in YTD Sept 2024)
• $853.0M — Long-term Debt (Sept 30, 2025) (Decreased from $905.07M at Dec 31, 2024)
• $38.9M — Cash & Cash Equivalents (Sept 30, 2025) (Increased from $24.46M at Dec 31, 2024)
• 30,967,954 — Shares Outstanding (Nov 3, 2025) (Current common stock shares outstanding)

Key Players & Entities

• CONMED Corp (company) — registrant
• $337.926 million (dollar_amount) — net sales for Q3 2025
• $2.859 million (dollar_amount) — net income for Q3 2025
• $171.807 million (dollar_amount) — cost of sales for Q3 2025
• $140.339 million (dollar_amount) — selling and administrative expense for Q3 2025
• $1.001 billion (dollar_amount) — net sales for nine months ended Sept 30, 2025
• $30.316 million (dollar_amount) — net income for nine months ended Sept 30, 2025
• $853.007 million (dollar_amount) — long-term debt as of Sept 30, 2025
• FASB (regulator) — Financial Accounting Standards Board
• NYSE (regulator) — stock exchange

FAQ

Risk Factors

• Significant Increase in Cost of Sales [high — operational]: Cost of sales rose by 24.8% to $171.807 million in Q3 2025, significantly outpacing net sales growth. This indicates potential supply chain pressures, increased raw material costs, or production inefficiencies that are eroding gross margins.
• Surge in Selling and Administrative Expenses [high — operational]: Selling and administrative expenses increased by 40.7% to $140.339 million in Q3 2025. This substantial rise, far exceeding sales growth, suggests increased operational costs, marketing investments, or potential inefficiencies in sales and administrative functions.
• Drastic Decline in Net Income and EPS [high — financial]: Net income for Q3 2025 plummeted by 94.2% to $2.859 million, with diluted EPS falling to $0.09 from $1.57. This sharp decline, despite higher sales, is a direct consequence of the escalating cost of sales and operating expenses.
• Inventory Growth [medium — financial]: Inventories increased to $364.355 million as of September 30, 2025, from $346.719 million at December 31, 2024. While some inventory build-up can be strategic, a significant increase alongside rising costs could indicate slower sales velocity or potential obsolescence risks.
• High Operating Expenses Relative to Gross Profit [high — financial]: Operating expenses (Cost of Sales + Selling & Admin + R&D) for Q3 2025 were $154.240 million, while gross profit was $166.119 million. This leaves a very thin margin for income from operations ($11.879 million), highlighting the pressure from rising costs.

Industry Context

CONMED operates in the medical device industry, a sector characterized by innovation, regulatory scrutiny, and intense competition. Companies in this space often face pressures from healthcare providers to manage costs while delivering advanced solutions. Trends include a focus on minimally invasive procedures, digital health integration, and supply chain resilience.

Regulatory Implications

As a medical device manufacturer, CONMED is subject to stringent regulations from bodies like the FDA. Changes in healthcare policy, reimbursement rates, and compliance requirements can significantly impact sales and operational costs. The company must maintain rigorous quality control and adhere to evolving global regulatory standards.

What Investors Should Do

1. Monitor cost of sales and SG&A trends closely.
2. Analyze gross and operating margins for signs of recovery.
3. Evaluate the drivers behind inventory growth.
4. Assess the company's strategy for cost management and operational efficiency.

Key Dates

• 2025-09-30: End of Third Quarter 2025 — Reporting period for the significant decline in net income despite sales growth, highlighting increased operational costs.
• 2024-12-31: End of Fiscal Year 2024 — Baseline for comparison of balance sheet items, showing an increase in total assets and cash, but a decrease in long-term debt.

Glossary

Cost of sales

The direct costs attributable to the production or purchase of the goods sold by a company. (A significant increase in cost of sales is the primary driver of CONMED's reduced net income, despite higher sales.)

Selling and administrative expense

Costs incurred by a company in the process of selling products and managing the business, excluding direct production costs. (A substantial rise in these expenses further contributed to the sharp decline in CONMED's profitability.)

Diluted EPS

Earnings per share calculated by dividing net income by the total number of diluted common shares outstanding, including the effect of all dilutive potential common shares. (CONMED's diluted EPS fell dramatically from $1.57 to $0.09, reflecting the severe impact of rising costs on profitability.)

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair value of its net assets. (Goodwill represents a significant portion of CONMED's assets ($806.9 million), indicating past acquisitions.)

Other intangible assets, net

Assets that lack physical substance but are identifiable and provide future economic benefits, such as patents, trademarks, and customer lists, net of amortization. (These assets are substantial ($593.1 million) and their net value decreased from the prior year-end, potentially due to amortization.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, CONMED Corp has experienced a significant deterioration in profitability. While net sales for Q3 2025 increased by 6.7% to $337.9 million and for the nine months by 4.2% to $1.001 billion, net income has collapsed by 94.2% and 69.3% respectively. This is primarily due to a substantial increase in the cost of sales (24.8% for Q3) and a dramatic rise in selling and administrative expenses (40.7% for Q3), which have severely impacted margins and earnings per share.

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value CNMD NYSE Indicate by check

Filing Documents

• cnmd-20250930.htm (10-Q) — 1195KB
• cnmd93025ex311.htm (EX-31.1) — 10KB
• cnmd93025ex312.htm (EX-31.2) — 10KB
• cnmd93025ex321.htm (EX-32.1) — 8KB
• 0000816956-25-000056.txt ( ) — 6964KB
• cnmd-20250930.xsd (EX-101.SCH) — 32KB
• cnmd-20250930_cal.xml (EX-101.CAL) — 60KB
• cnmd-20250930_def.xml (EX-101.DEF) — 148KB
• cnmd-20250930_lab.xml (EX-101.LAB) — 537KB
• cnmd-20250930_pre.xml (EX-101.PRE) — 361KB
• cnmd-20250930_htm.xml (XML) — 1257KB

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION Item Number Page Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) – Consolidated Condensed Statements of Comprehensive Income for the three and nine months ended September 3 0 , 2025 and 2024 1 – Consolidated Condensed Balance Sheets as of September 3 0 , 2025 and December 31, 2024 2 – Consolidated Condensed Statements of Shareholders' Equity for the nine months ended September 3 0 , 2025 and 2024 3 – Consolidated Condensed Statements of Cash Flows for the nine months ended September 3 0 , 2025 and 2024 5 – Notes to Consolidated Condensed Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 28 Item 4.

Controls and Procedures

Controls and Procedures 28

OTHER INFORMATION

PART II OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 28 Item 5. Other Information 28 Item 6. Exhibits 29

Signatures

Signatures 30 Table of Contents

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION Item 1. CONMED CORPORATION CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited, in thousands except per share amounts) Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 Net sales $ 337,926 $ 316,701 $ 1,001,526 $ 961,071 Cost of sales 171,807 137,706 469,336 426,383 Gross profit 166,119 178,995 532,190 534,688 Selling and administrative expense 140,339 99,730 425,207 345,611 Research and development expense 13,901 13,558 40,985 41,250 Operating expenses 154,240 113,288 466,192 386,861 Income from operations 11,879 65,707 65,998 147,827 Interest expense 7,606 9,252 23,716 28,440 Other expense — — 418 — Income before income taxes 4,273 56,455 41,864 119,387 Provision for income taxes 1,414 7,471 11,548 20,719 Net income $ 2,859 $ 48,984 $ 30,316 $ 98,668 Comprehensive income $ 6,605 $ 48,701 $ 39,941 $ 94,121 Per share data: Net income Basic $ 0.09 $ 1.59 $ 0.98 $ 3.20 Diluted 0.09 1.57 0.97 3.17 Weighted average common shares Basic 30,955 30,856 31,027 30,815 Diluted 31,050 31,112 31,145 31,148 See notes to consolidated condensed financial statements. 1 Table of Contents CONMED CORPORATION CONSOLIDATED CONDENSED BALANCE SHEETS (Unaudited, in thousands except share and per share amounts) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 38,929 $ 24,459 Accounts receivable, net 224,943 237,733 Inventories 364,355 346,719 Prepaid expenses and other current assets 33,931 31,096 Total current assets 662,158 640,007 Property, plant and equipment, net 112,036 115,793 Goodwill 806,916 805,358 Other intangible assets, net 593,107 617,663 Other assets 148,271 127,426 Total assets $ 2,322,488 $ 2,306,247 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Current portion of long-term debt $ 746 $ 715 Accounts payable 107,087 102,248 Accrued compensation and benefits 76,125 65,

View Full Filing

View this 10-Q filing on SEC EDGAR